WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells

Oncogene

Volumn 32, Issue 11, 2013, Pages 1441-1451

  Mackintosh, C ^a   Garcia Dominguez D J ^a   Ordonez J L ^a   Ginel Picardo, A ^a   Smith, P G ^b   Sacristan M P ^a   De Alava E ^a,c  

^a Centro de Investigacion del Cancer   (Spain)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

cyclin A; cyclin E; Ewing sarcoma; MLN4924; P27; WEE1

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; CELL CYCLE PROTEIN 6; CYCLIN A; CYCLIN E; PHOSPHOTRANSFERASE; PROTEIN P27; UNCLASSIFIED DRUG; WEE1 KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; DNA DAMAGE; ENZYME INHIBITION; EWING SARCOMA; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLOPENTANES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED C57BL; NUCLEAR PROTEINS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RNA, SMALL INTERFERING; S PHASE; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875227094     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.153     Document Type: Article

References (41)

1. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA et al. Ewing0s sarcoma family of tumors: Current management. Oncologist 2006; 11: 503-519. (Pubitemid 43788277)
2. Haeusler J, Ranft A, Boelling T, Gosheger G, Braun-Munzinger G, Vieth V et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116: 443-450.
3. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-Bosch A, Szuhai K et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 2012; 31: 1287-1298.
4. Cardozo T, Pagano M. The SCF ubiquitin ligase: Insights into a molecular machine. Nat Rev Mol Cell Biol 2004; 5: 739-751. (Pubitemid 39208183)
5. Bennett EJ, Rush J, Gygi SP, Harper JW. Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 2010; 143: 951-965.
6. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449. (Pubitemid 351744963)
7. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009; 458: 732-736.
8. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, Schulman BA et al. Structural insights into NEDD8 activation of cullin-RING ligases: Conformational control of conjugation. Cell 2008; 134: 995-1006.
9. Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K et al. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics. (e-pub ahead of print 2011; doi:10.1074/mcp.M111.009183).
10. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199. (Pubitemid 129500937)
11. Yu ZK, Gervais JL, Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 1998; 95: 11324-11329.
12. Tan P, Fuchs SY, Chen A, Wu K, Gomez C, Ronai Z et al. Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol Cell 1999; 3: 527-533. (Pubitemid 29292610)
13. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci USA 2004; 101: 4419-4424. (Pubitemid 38437427)
14. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV et al. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003; 426: 87-91. (Pubitemid 37432546)
15. Singer JD, Gurian-West M, Clurman B, Roberts JM. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev 1999; 13: 2375-2387. (Pubitemid 29453609)
16. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010; 116: 1515-1523.
17. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H et al. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer (e-pub ahead of print 2011; doi: 10.1002/pbc.23357).
18. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U et al. Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010; 49: 40-51.
19. Lin JJ, Milhollen MA, Smith PG, Narayanan U, Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 2010; 70: 10310-10320.
20. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, Amidon B et al. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 2011; 71: 3042-3051.
21. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004; 6: 661-672. (Pubitemid 38579350)
22. Susaki E, Nakayama KI. Multiple mechanisms for p27(Kip1) translocation and degradation. Cell Cycle 2007; 6: 3015-3020.
23. Syljuasen RG, Jensen S, Bartek J, Lukas J. Adaptation to the ionizing radiationinduced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 2006; 66: 10253-10257. (Pubitemid 44799740)
24. Bartek J, Lukas J. Chk1and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3: 421-429. (Pubitemid 38340288)
25. McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993; 12: 75-85. (Pubitemid 23042384)
26. Watanabe N, Broome M, Hunter T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J 1995; 14: 1878-1891.
27. Jiang W, Wells NJ, Hunter T. Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6. Proc Natl Acad Sci USA 1999; 96: 6193-6198. (Pubitemid 29256642)
28. Petersen BO, Lukas J, Sorensen CS, Bartek J, Helin K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J 1999; 18: 396-410. (Pubitemid 29041948)
29. Paolinelli R, Mendoza-Maldonado R, Cereseto A, Giacca M. Acetylation by GCN5 regulates CDC6 phosphorylation in the S phase of the cell cycle. Nat Struct Mol Biol 2009; 16: 412-420.
30. Nishitani H, Sugimoto N, Roukos V, Nakanishi Y, Saijo M, Obuse C et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J 2006; 25: 1126-1136. (Pubitemid 43372125)
31. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E et al. Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia. Blood 2010; 115: 3796-3800.
32. Jia L, Li H, Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 2011; 13: 561-569.
33. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A et al. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011; 44: 325-340.
34. Grimmler M, Wang Y, Mund T, Cilensek Z, Keidel EM, Waddell MB et al. Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases. Cell 2007; 128: 269-280. (Pubitemid 46123508)
35. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007; 128: 281-294. (Pubitemid 46123510)
36. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP et al. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996; 382: 325-331. (Pubitemid 26260452)
37. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9: 661-664.
38. Vigo E, Muller H, Prosperini E, Hateboer G, Cartwright P, Moroni MC et al. CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. Mol Cell Biol 1999; 19: 6379-6395. (Pubitemid 29399342)
39. Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010; 18: 244-257.
40. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS et al. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 2012; 72: 282-293.
41. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U et al. Molecular characterization of commonly used cell lines for bone tumor research: A trans-European EuroBoNet effort. Genes Chromosomes Cancer 2010; 49: 40-51.